Verrica Pharmaceuticals Inc (VRCA) USD0.0001
0.32%- This stock can be held in a
Stocks and Shares ISA
$0.04
(8.20%)$0.04
(8.20%)Company Information
About this company
Verrica Pharmaceuticals Inc. is a dermatology therapeutics company developing and selling medications for skin diseases requiring medical intervention. The Company's product portfolio consists of one approved product with several potential follow-on indications, as well as an additional pipeline product. Its commercial product, YCANTH (VP-102), is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin. It is engaged in developing YCANTH (VP-102) for the treatment of molluscum contagiosum in adult and pediatric patients two years of age and older. It is also developing YCANTH (VP-102) for a potential follow-on indication for the treatment of common warts. Its second development candidate, VP-315, is an oncolytic peptide-based injectable therapy for the potential treatment of dermatology oncologic conditions, including basal cell carcinoma (BCC).
Key people
Key facts
- EPICVRCA
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- ISINUS92511W1080
- Market cap$49.93m
- Employees71
- Shares in issue92.60m
- ExchangeNASDAQ
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.